Scinai Immunotherapeutics Ltd. (SCNI) stock
SCNINasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.75−0.00 (-0.32%)
Close on Oct 19, 2026Market cap –P/E –Yield –
Scinai Immunotherapeutics net income
Net income is the profit left for shareholders after every expense, interest and tax.
For fiscal 2025 it was -$8.31M, down 273.2% from the year before. The highest annual figure on record is $4.80M in fiscal 2024.
Annual net income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$8.31M | -273.2% |
| FY2024 | Dec 31, 2024 | $4.80M | – |
| FY2023 | Dec 31, 2023 | -$6.50M | – |
| FY2022 | Dec 31, 2022 | -$5.80M | – |
| FY2021 | Dec 31, 2021 | -$8.21M | – |
Quarterly net income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2023 | Jun 30, 2023 | -$3.76M | – |
| Q1 FY2023 | Mar 31, 2023 | -$3.52M | – |
| Q2 FY2022 | Jun 30, 2022 | -$2.98M | – |
| Q1 FY2022 | Mar 31, 2022 | -$2.48M | – |
See a number that looks wrong?